Page 24 - Ace2 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Researchers explore an inhalable SARS-CoV-2 nanobody therapy The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the world’s third major coronavirus outbreak. To date, the SARS-CoV-2 has infected over 135 million lives and caused over 2.9 million deaths. Even as vaccines against SARS-CoV-2 are being developed and administered at an unprecedented pace, treating this infection remains a challenge. To address this, researchers from China have used nanobodies (Nb) as a possible therapeutic approach. In a recent paper, pu...

Previously approved drugs starting points for COVID-19 therapeutics Researchers in the United States have identified several clinically approved compounds that could be repurposed for the treatment and prevention of coronavirus disease 2019 (COVID-19). By screening a commercial library of drugs that have already been approved by international regulatory agencies, the team identified more than 50 compounds that demonstrated some efficacy in blocking the initial stage of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative agent of COVID-19. The compound...

COVID19's cytokine storm ushers in a local complement storm in the lungs A new study published in the journal Science Immunology analyzed lung epithelial cells from patients infected with COVID-19 and found the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces the complement system as a dangerous weapon for viral infection. The complement system is an extension of the innate immune system to recognize pathogens and remove them. Prior research has shown a correlation between severe COVID-19 infection and high levels of complement. The mechanism of action is driving the JAK1...

Researchers provide ultrastructural details of SARS-CoV-2-infected respiratory epithelial cells A team of scientists from the United Kingdom recently investigated the ultrastructural details of the attachment, entry, and budding processes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the human airway epithelium. They have used a highly differentiated air-liquid interface cultures of airway epithelium to thoroughly investigate the viral infection cycle. The study is currently available on the Background SARS-CoV-2, the causative pathogen of coronavirus disease 2019 (COVID...

Why post-vaccine rashes could be a 'good thing' Marlene Cimons, The Washington Post April 11, 2021 FacebookTwitterEmail Kaiser Doctor Allison Friedenberg (left) receivies a Pfizer COVID-19 vaccine shot from Nurse Scott Keech at Kaiser San Francisco hospital on December 7, 2020 in San Francisco, California.Douglas Zimmerman / SFGATE Tina Burke, 40, a nurse who works on the oncology floor at Massachusetts General Hospital (MGH), received her first coronavirus shot on Jan. 3. Six days later, she developed a rash on her injected arm but "thought nothing of it." The next morning, however, she wok...